强化性培美曲塞解救化疗实体性肿瘤的临床观察  

The clinical observation of intensified pemetrexed for solid tumor

作　　者：张宁 张燕军 雷宝霞 苏智祥 吴兴树 崔大江[2] 狄灵[2] 

机构地区：[1]陕西省肿瘤医院,西安710061 [2]西安交通大学附属西北医院,西安710061

出　　处：《中国肿瘤临床与康复》2012年第3期228-231,共4页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的观察培美曲塞在750～800mg/m2时的不良反应,分析血液学毒性与既往化疗强度的相关性及客观疗效。方法采用开放、非随机方法收集28例患者,培美曲塞(PEM)每个疗程总剂量750～800mg/m2,分第1、8天静脉滴注10min以上,每3～4周重复。每2个疗程评价疗效,治疗至患者病情进展、出现严重不良反应或患者自动退出。结果 28例患者全部可评价不良反应,3/4度骨髓抑制的发生率为14.3%,既往出现过类似反应患者的发生率为36.4%。26例可评价疗效的患者中,有效率为19.2%,稳定率为61.5%;既往进行3种以下方案化疗组与3种或以上方案组之间的有效率,分别为16.7%和21.4%,稳定率分别为58.3%和64.3%。15例非小细胞肺癌患者,有效率为20%,稳定率为60%。结论 PEM 750～800mg/m2是安全的,既往化疗出现3/4度骨髓抑制是严重血液学毒性的高危因素,结果显示可提高患者的客观疗效。Objective To evaluate the efficacy and adverse of 750 -800mg/m^2 pemetrexed. The relevance between the adverse and history chemotherapy was considered. Methods The cases were selected in opening and nonrandom. The pemetrexed were used in 750 - 800mg/m^2 in every treatment cycle, and were intravenous injection more than 10 minutes in one and eight day. The efficacy was evaluated after two weeks and the case with serious adverse was out of treatment. Results All of 28 cases were evaluated . There were 14. 3% cases come with 3/4 degree marrow inhibition. The degree marrow incidence was 36. 4% in the cases with previous inhibition history and was 0% in the cases without previous history. The efficient rate and stability rate were 19.2% and 61.5%, respectively. There was no significant difference between less than and more than 3 kinds of chemotherapy protocols. Conclusions The treatment of 750 - 800mg/m^2 pemetrexed was safe and the previous inhibition history was high risk factors.

关 键 词：培美曲塞 化疗 强化化疗 安全性 有效性 临床观察 

分 类 号：R730.53[医药卫生—肿瘤]